drugset / Trial / NCT03973879
Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the safety of PVSRIPO treatment in combination with Atezolizumab in patients with WHO grade IV malignant glioma. All patients will receive a single PVSRIPO infusion followed by atezolizumab infusions every three weeks for up to two years.
Timeline
- Start
- 2020-02
- Primary completion
- 2024-01
- Completion
- 2024-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | — |
| Subject | PVSRIPO | Other / unclassified | 5e+07 unknown | Other |